VENATORX PHARMACEUTICALS, INC.

Address

30 Spring Mill Drive
Malvern, PA, 19355-1200

Information

DUNS: 962754037
# of Employees: 18

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Discovery of inhibitors of Zika virus

    Amount: $299,999.00

    PROJECT SUMMARY Novel inhibitors of Zika virus ZIKV are urgently needed to prevent the occurrence of virus induced microcephaly and Guillain Barr syndrome The objective of this Phase I SBIR feasib ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Discovery of inhibitors of BK polyomavirus

    Amount: $347,101.00

    PROJECT SUMMARY Novel inhibitors of BK polyomavirus BKPyV are urgently needed to prevent the occurrence of virus induced nephropathy allograft failure and hemorrhagic cystitis following transplanta ...

    SBIRPhase I2016Department of Health and Human Services
  3. Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series

    Amount: $1,139,136.00

    DESCRIPTION provided by applicant Novel therapies for the treatment of Chikungunya virus CHIKV infections are urgently needed to address the alarming spread of this pathogen across the Americas ...

    SBIRPhase II2016Department of Health and Human Services
  4. Discovery and Advancement of Chikungunya virus inhibitors

    Amount: $600,000.00

    DESCRIPTION provided by applicant Novel inhibitors of Chikungunya virus CHIKV are urgently needed to address the alarming spread of this pathogen across the Americas The objective of this Phase ...

    SBIRPhase I2015Department of Health and Human Services
  5. Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

    Amount: $600,000.00

    DESCRIPTION provided by applicant This year Phase I SBIR Application centers on completing the lead optimization of an andquot ultra broad spectrumandquot carbapenem UBSC lead series with an u ...

    SBIRPhase I2015Department of Health and Human Services
  6. Broad-spectrum, orally-bioavailable beta-lactamase inhibitors

    Amount: $599,200.00

    DESCRIPTION provided by applicant Broad spectrum orally bioavailable lactam antibiotics play a critical role in the management of human infectious diseases both in the hospital and community se ...

    SBIRPhase I2014Department of Health and Human Services
  7. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    Amount: $3,000,000.00

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super ...

    SBIRPhase II2013Department of Health and Human Services
  8. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    Amount: $3,000,000.00

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by th ...

    SBIRPhase II2013Department of Health and Human Services
  9. Novel Compounds Targeting Bacterial PBPs

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiot ...

    SBIRPhase I2012Department of Health and Human Services
  10. Novel Metallo-beta-lactamase Inhibitors

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as ...

    SBIRPhase I2011Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government